Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Loder

Podiatrist, Foot & Ankle Surgery Clinton Township, MI Doctor of Podiatric Medicine

NPI 1184629180 CMS profile 189516

43391 Commons Dr, Clinton Township, MI 48038

Open in the dashboard

General payments

$853,938

520 records reported · program years 2019–2025

Research payments

$55,650

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$38,982 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Brian Loder of Clinton Township, MI is reported in the CMS Open Payments database as having received $853,938 across 520 general payments and $55,650 in research payments paid to them. Separately, studies naming them as principal investigator received $38,982 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $323,527 196
2024 General $171,444 78
2023 General $119,614 88
2022 General $82,740 55
2021 General $60,328 26
2020 General $36,654 18
2020 Research $24,450 1
2019 General $59,631 59
2019 Research $31,200 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Loder
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Brian Loder were reported at $323,527. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Brian Loder Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $59,631 $389 $118–$1,406 $163
2020 $36,654 $191 $62–$691 $114
2021 $60,328 $329 $104–$1,341 $132
2022 $82,740 $419 $125–$1,611 $149
2023 $119,614 $377 $128–$1,164 $160
2024 $171,444 $394 $134–$1,168 $164
2025 $323,527 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novastep Inc. $440,237 115 payments
  2. Treace Medical Concepts, Inc. $365,134 259 payments
  3. Medical Device Business Services, Inc. $40,180 35 payments
  4. Synthes USA Products LLC $3,617 2 payments
  5. Wright Medical Technology, Inc. $1,889 5 payments
  6. Stryker Corporation $481 10 payments
  7. Nevro Corp. $418 17 payments
  8. DePuy Synthes Sales Inc. $350 11 payments
  9. Smith+Nephew, Inc. $310 9 payments
  10. Organogenesis Inc. $268 13 payments
  11. Other $1,053 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $408,696 129 payments
  2. Royalty or License $364,035 51 payments
  3. Travel and Lodging $61,242 110 payments
  4. Food and Beverage $13,056 229 payments
  5. Education $6,909 1 payment
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM 1 $228,988 102 payments
  2. NEXIS Joint Implants $158,767 14 payments
  3. NEXIS Joint Implants $158,767 14 payments
  4. PECA Bunion Correction System $152,965 67 payments
  5. LAPIPLASTY SYSTEM $126,335 83 payments
  6. PECAPLASTY $58,669 12 payments
  7. VA-LCP PLATES & SCREWS $22,956 19 payments
  8. ANGLED BLADE PLATES $15,394 4 payments
  9. PECA-C Compressive Implants $13,585 7 payments
  10. CENTROLOCK MIS Bunion Correction $6,078 1 payment
  11. Other $21,280 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Skye Orthobiologics LLC $55,650 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

470

Median for Podiatry: 160

Drug cost

$4,039

Median for Podiatry: $2,368

Branded share of claims

56.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 86 $1,520
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 155 $941
Doxycycline Hyclate Generic 13 $333
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 66 $254
Cephalexin Generic 24 $200
Ibuprofen Generic 18 $152
Ssd Silver Sulfadiazine Brand 19 $139
Clindamycin Hcl Generic 14 $107
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 11 $97
Pregabalin Generic 11 $90

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$5,291,885

Of which drugs: $3,965,431

Medicare patients

248

Average age 73

Services billed

6,872

150 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 52%
Chronic kidney disease 43%
Ischemic heart disease 40%
Heart failure 35%
Atrial fibrillation 26%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Biovance tri-layer or biovance 3l, per square centimeter Q4283 Office 11 707 $830,266
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 108 $63

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

522 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record